Skip to main content

Table 1 Distribution of genotypes in the ten SNPs determined in BRCA1 mutation carriers with breast or ovarian cancer before 40 years of age (young cancer) and in carriers not having had breast or ovarian cancer before 60 years of age (old no cancer), and with calculated RR and OR, and HR/OR from previous reports [according to references given in left column]

From: Ten modifiers of BRCA1 penetrance validated in a Norwegian series

SNP

Genotype

Young cancer (number of cases)

Old no cancer (number of cases)

Reported risk

ObservedRR (95 % CI)

ObservedOR (95 % CI)

Fishers’ exact p – one sided

rs13387042 2q35 [4]

GG

13

18

 

1

-

 

AA

9

9

HR 1.05

1.19 (0.64–2.22)

1.38 (0.43–4.45)

0.40

GA

17

11

HR 1.14

1.45 (0.87–2.41)

2.14 (0.76–6.06)

0.12

AA or GA

26

20

 

1.35 (0.83–2.19)

1.80 (0.72–4.52)

0.15

rs3803662 16q12 TOX3, LOC643714 [5]

CC

18

26

 

1

-

 

TT

1

2

HR 1.24

0.81 (0.16–4.20)

0.72 (0.06–8.58)

0.65

CT

20

10

HR 1.11

1.63 (1.05–2.52)

2.89 (1.10–7.61)

0.03*

TT or CT

21

12

 

1.56 (1.00–2.41)

2.53 (1.00–6.40)

0.04*

rs8170 19p13 [6]

GG

29

27

 

1

-

 

AA

0

1

HR 1.35

-

-

-

GA

11

10

HR 1.22

1.01 (0.63–1.63)

1.02 (0.38–2.80)

0.58

AA or GA

11

11

 

0.97 (0.59–1.57)

0.93 (0.35–2.50)

0.65

rs9397435 6q25 ESR1 [7]

AA

32

34

 

1

-

 

GG

1

0

HR 1.37

2.06 (1.61–2.64)

-

-

AG

7

4

HR 1.31

1.31 (0.79–2.19)

1.86 (0.50–6.96)

0.27

GG or AG

8

4

 

1.38 (0.86–2.20)

2.13 (0.58–7.75)

0.20

rs700518 CYP19 [8]

AA

12

14

 

1

-

 

GG

16

6

OR 2.81

1.58 (0.97–2.57)

3.11 (0.92–10.48)

0.06

AG

11

17

OR 1.41

0.85 (0.46–1.58)

0.75 (0.26–2.23)

0.41

GG or AG

27

23

 

1.17 (0.72–1.91)

1.37 (0.53–3.54)

0.34

rs10046 CYP19 [9]

CC

11

15

 

1

-

 

TT

17

7

OR 1.37

1.67 (1.00–2.81)

3.31 (1.02–10.72)

0.04*

TC

12

15

OR 1.26

1.05 (0.57–1.94)

1.09 (0.37–3.23)

0.55

TT or TC

29

22

0R 1.29

1.34 (0.81–2.23)

1.80 (0.69–4.67)

0.17

rs3834129 CASP 8 [10]

nor/nor

8

9

 

1

-

 

del/del

12

6

HR 1.60

1.42 (0.78–2.58)

2.25 (0.57–8.82)

0.20

nor/del

19

23

HR 1.83

0.96 (0.53–1.76)

0.93 (0.30–2.88)

0.56

del/del or nor/del

31

29

 

1.10 (0.63–1.92)

1.20 (0.41–3.54)

0.48

rs1045485 CASP 8 [11]

GG

33

25

 

1

-

 

CC

1

6

HR 0.86

0.25 (0.04–1.56)

0.13 (0.01–1.12)

0.04*

GC

5

5

HR 0.83

0.88 (0.45–1.70)

0.76 (0.20─2.91)

0.47

CC or GC

6

11

 

0.62 (0.31─1.23)

0.41 (0.13─1.27)

0.10

rs2363956 9p13 ABHD8, ANKLE1, C19orf62 [12]

AA

15

5

 

1

-

 

CC

7

13

HR 0.7

0.47 (0.24–0.89)

0.18 (0.05–0.70)

0.01*

AC

18

19

HR 0.89

0.65 (0.43–0.98)

0.32 (0.10–1.05)

0.05*

CC or AC

25

32

 

0.58 (0.40–0.86)

0.26 (0.08–0.81)

0.02*

rs16942 BRCA1 [13] 

TT

20

23

 

1

-

 

CC

5

9

HR 0.85

0.77 (0.35–1.66)

0.64 (0.18–2.22)

0.35

TC

15

6

 

1.54 (1.01–2.34)

2.88 (0.94–8.82)

0.05*

CC or TC

20

15

 

1.23 (0.80–1.89)

1.53 (0.62–3.77)

0.24

  1. *: p < = 0.05